BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-09 4:45 pm Purchase | 2024-01-05 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 5,831,171 9.990% | 1,138,567 (+24.26%) | Filing |
| 2022-08-23 4:45 pm Purchase | 2022-08-22 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 4,692,604 8.600% | 553,846 (+13.38%) | Filing |
| 2022-06-01 5:00 pm Purchase | 2022-05-27 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 4,138,758 8.000% | 552,100 (+15.39%) | Filing |
| 2022-01-31 5:07 pm Purchase | 2022-01-27 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 3,586,658 7.000% | 955,996 (+36.34%) | Filing |
| 2020-08-25 5:27 pm Purchase | 2020-08-21 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 2,630,662 5.900% | 2,630,662 (New Position) | Filing |